Synthetic clinical data generation creates artificial patient records, notes, images, claims and device data that reproduce the statistical patterns and clinical realism of real healthcare data without belonging to real people. Teams use it to build, test and demonstrate healthcare software and AI faster, share data safely and reduce privacy risk from using real PHI.
Most healthcare AI and software projects lose weeks waiting for access to real patient data, then carry privacy risk once they get it. Synthetic data changes that timeline: developers can start building on day one, vendors can demonstrate products without PHI and test suites can cover rare cases real data rarely contains. Taction Software generates healthcare synthetic data drawing on 200+ healthcare projects since 2013, extending our healthcare synthetic data generation services.
Our experts are ready to understand your business goals.
Synthetic data is not a replacement for real data in every situation, but it removes real data from many steps where it was never truly needed. Development environments, automated tests, product demonstrations, training exercises and early AI prototyping can often run entirely on well-designed synthetic data. Real data is then reserved for final validation, where it matters most. That shift reduces privacy exposure and speeds delivery. The six uses below are where healthcare organizations and technology companies gain the most from synthetic clinical data, often within the first weeks of adopting it across teams.
Developers build and test healthcare applications against realistic synthetic patients, encounters, medications and results instead of copies of production databases. Development environments no longer hold PHI, which removes one of the most common and least justified sources of healthcare data exposure in engineering teams.
AI teams test model approaches, pipelines and interfaces on synthetic data before real data access is approved. Our guide to synthetic patient data for AI prototyping explains how prototypes built this way reach real-data validation faster and with fewer surprises.
HL7 messages, FHIR resources and claims files generated synthetically let teams test interfaces end to end, including unusual message variations and edge cases. Partners can exchange test data freely, speeding integration projects that otherwise stall waiting for approved sample messages from production systems.
Health technology companies demonstrate products to prospects using synthetic patients that look and behave realistically. Sales teams never need production data or de-identified exports, and demonstrations can showcase specific clinical scenarios that highlight product strengths for each type of buyer.
Clinicians and staff learn new systems, workflows and AI tools using synthetic patients with realistic histories. Training environments feel authentic without exposing real records, and scenarios can be designed to teach specific skills, including rare situations staff might otherwise never practice before encountering them.
Real datasets contain few examples of rare conditions, unusual combinations and edge cases. Synthetic generation can create targeted examples to test how software and AI behave in these situations, improving robustness without waiting years to collect enough real cases for meaningful testing.
Many organizations use real patient data far more widely than necessary, simply because no good alternative exists. Copies of production databases live in test environments, vendors receive de-identified exports that carry residual risk, and AI projects stall for months waiting on data approvals. These patterns create privacy exposure and slow delivery at the same time. If two or more of the six signs below describe your organization, synthetic clinical data is likely to reduce risk and accelerate work, and a short assessment can confirm which datasets to generate first. Most organizations recognize several.
If development or test environments hold copies of production data, you carry privacy risk in systems that rarely have production-level security. Replacing those copies with synthetic data is one of the fastest ways to reduce your overall HIPAA exposure without slowing engineering work.
If AI projects spend months waiting for data use approvals before any building starts, synthetic data lets teams begin immediately. Development, pipeline building and early testing proceed in parallel with approvals, and real data is used only when validation actually requires it.
If partners and vendors regularly request sample data for integration or evaluation, each request creates risk and paperwork. Synthetic datasets can be shared freely, speeding partnerships and removing the need to review and approve exports for every new vendor conversation.
If sales demonstrations or training sessions use real patient records or crudely masked data, the organization is exposed. Realistic synthetic patients remove that risk entirely and often make demonstrations more effective, because scenarios can be tailored to each audience. Prospects notice professionalism.
If software defects keep appearing in production for unusual cases, your test data probably lacks them. Synthetic generation can create specific edge cases, such as rare conditions, unusual message formats or extreme values, so testing covers situations real samples rarely include.
If your teams are uncomfortable with residual re-identification risk in de-identified datasets, synthetic data offers another option for many uses. It does not remove all privacy considerations, but well-designed synthetic data can substantially reduce risk compared with sharing real records.
Healthcare data takes many forms, and each needs a different generation approach to stay realistic. Structured records must follow clinical logic, such as medications matching diagnoses and labs changing plausibly over time. Clinical notes must read naturally while matching structured data, and interface messages must follow standards exactly. Images and signals require specialized generative techniques. The six data types below are the ones we generate most often, and they can be combined into consistent synthetic patients whose records, notes, messages and claims all tell the same clinical story. Each is validated before delivery.
We generate patients with demographics, conditions, encounters, medications, allergies, procedures and lab results that follow realistic clinical progressions. Open-source tools such as Synthea provide useful foundations, which we extend with custom clinical logic, local code sets and population characteristics that match your use case.
Synthetic data is produced as valid FHIR resources conforming to profiles such as US Core, ready for API testing, app development and interoperability work. Our FHIR API development team validates resources against implementation guides your partners and regulators expect. Invalid resources never ship.
We generate ADT, order, result and scheduling messages with realistic content and controlled variations, including malformed messages for negative testing. Synthetic HL7 feeds let interface teams test channels thoroughly before connecting to production. Our HL7 ADT integration services use them.
Synthetic notes, such as progress notes, discharge summaries and referral letters, are generated to match each patient’s structured record. Notes include realistic abbreviations, templates and variation, supporting NLP, RAG and documentation AI development without exposing real clinician documentation containing PHI.
Synthetic claims, remittances and eligibility data follow payer rules and coding patterns, supporting revenue cycle software, analytics and payer platform development. Financial scenarios, such as denials, underpayments and appeals, can be generated deliberately to test how systems handle difficult cases.
We generate vital signs, glucose readings, activity data and other device streams with realistic patterns, noise and alert-worthy events. Synthetic monitoring data supports remote patient monitoring software development, alert testing and analytics before real device deployments begin. Alert thresholds can be tested safely.
Synthetic data is only useful if it is realistic enough for its purpose and private enough to use safely. Poor synthetic data teaches AI the wrong patterns and gives testers false confidence, while synthetic data generated carelessly from real records can still leak information about real patients. Evaluation must measure both utility and privacy, using methods matched to how the data will be used. The six evaluation practices below are applied to every synthetic dataset we produce, and results are documented so your privacy, security and data governance teams can approve its use confidently.
We compare distributions, correlations and trends in synthetic data against target characteristics or aggregate statistics, checking that age mixes, condition prevalence, lab ranges and utilization patterns look realistic. Fidelity reports show where synthetic data matches reality and where it intentionally differs.
Clinical reviewers check that synthetic patients make medical sense: medications match diagnoses, lab trends fit conditions and care sequences follow realistic pathways. Plausibility review catches errors statistical tests miss, such as impossible combinations that would confuse clinicians or mislead AI models.
We test whether synthetic data serves its purpose, such as training a model that performs comparably on real validation data or exercising every code path in an application. Utility testing confirms synthetic data is genuinely useful, not just statistically similar in summary tables.
When synthetic data is generated from real data, we assess risks such as records too similar to real patients or membership inference. Privacy metrics and controls, such as distance checks and noise, reduce the chance that synthetic records reveal anything about real individuals.
HIPAA recognizes Safe Harbor and Expert Determination methods for de-identification. Where synthetic data is derived from real records, we document how the process relates to these standards and work with qualified experts when a formal determination is required for your use case.
Every synthetic dataset is labeled clearly as synthetic and documented with its generation method, parameters, intended uses and limitations. Clear labeling prevents synthetic records from being mistaken for real patients and helps teams understand where the data should and should not be used.
Choosing between synthetic, de-identified and real patient data depends on the task, the risk and the stage of work. Each option has a place, and mature healthcare organizations use all three deliberately rather than defaulting to real data everywhere. Synthetic data suits development and testing, de-identified data suits many analytics and research tasks, and real data remains essential for clinical validation and care delivery. Matching data type to purpose reduces privacy exposure without slowing progress. The six comparisons below help teams decide which type of data fits each stage of a healthcare software or AI project.
Synthetic data fits development, automated testing, demonstrations, training environments, interface testing and early AI prototyping. These uses need realistic structure and behavior but not real patients, so synthetic data delivers speed and safety without meaningful loss of value for the work being done.
De-identified real data fits analytics, research and model training where true population patterns matter. Our PHI redaction services de-identify records and notes, but residual re-identification risk must still be assessed and governed carefully for each dataset and each intended use.
Real patient data is required for clinical care, final AI validation, regulatory evidence and production monitoring. Synthetic data cannot prove that a model works on your patients, so validation on real data under proper governance remains essential before clinical deployment of any AI system.
Synthetic data is available immediately, de-identified data usually takes weeks for approvals and processing, and real data access can take months for AI projects. Using synthetic data first lets development proceed while approvals for de-identified or real data move forward in parallel.
Synthetic data generated without real records carries the lowest privacy risk, de-identified data carries residual risk that must be managed, and real data carries full HIPAA obligations. Choosing the lowest-risk option that still meets each task’s needs is a practical application of minimum necessary.
Most successful programs combine all three: synthetic data for building, de-identified data for learning patterns and real data for validation and care. We help teams design data strategies that move each project through these stages efficiently, safely and with clear governance approvals.
We deliver synthetic clinical data as focused dataset projects, as reusable generation pipelines your teams can run themselves, or as part of AI and software builds through our productized pathway. Every engagement starts by defining the uses, data types and quality thresholds the synthetic data must meet. Work on standalone datasets and pipelines is billed at our $50 blended hourly rate, and the ranges below are planning figures, not quotes. The six options below describe how organizations engage us, and our healthcare AI proof of concept work often begins with synthetic data.
A defined synthetic dataset, such as a test patient population with FHIR resources and HL7 messages, typically takes 80 to 300 hours. Scope depends on data types, population size, clinical complexity and the fidelity and privacy evaluation required for its intended use.
A reusable pipeline your teams can run to generate fresh synthetic data on demand typically takes 300 to 1,000 hours. Pipelines include configuration for populations and scenarios, output in required formats and automated quality checks for every generated dataset. Teams stop waiting on data.
Synthetic data generated from your real data requires privacy risk assessment, governance approval and expert involvement where formal de-identification determinations are needed. This work is scoped after reviewing your data, uses and privacy requirements with your compliance team. Governance stays in control.
For AI projects, synthetic data is often built into our productized pathway, starting with a $45,000 Discovery Sprint, so prototyping and pipeline development begin on synthetic data while real data access is approved in parallel. Weeks of waiting become weeks of progress.
Teams with ongoing needs can hire synthetic health data engineers at about $8,000 per engineer per month to build, maintain and extend synthetic data generation alongside internal engineering, QA and data science teams. They can usually start within weeks and work inside your existing tools.
Synthetic data needs updating as code sets, standards and product requirements change. Maintenance retainers typically cover 20 to 80 hours per month, costing $1,000 to $4,000, keeping datasets and pipelines aligned with current vocabularies and formats. Datasets stay current and trustworthy.
Two questions matter when choosing a synthetic data partner: can they make data clinically realistic enough to be genuinely useful, and can they demonstrate it is safe to use. Generic synthetic data tools often produce records that look plausible in tables but fail clinical review or interface validation. Our team combines clinical data expertise, healthcare standards knowledge and privacy engineering, drawing on 200+ healthcare projects since 2013 and ISO 27001 certified processes. We sign Business Associate Agreements whenever work involves real PHI. The six points below explain what working with us looks like.
Our synthetic patients follow realistic clinical logic, reviewed for plausibility, so developers, testers and AI models work with data that behaves like real care. That realism is what makes synthetic data useful beyond superficial demonstrations and basic smoke tests. Reviewers confirm it.
FHIR resources validate against profiles, HL7 messages follow specifications and claims follow coding rules. Our integration engineers use the same data in real projects, so synthetic output works in interfaces and APIs, not just in spreadsheets or reports. Validation runs automatically.
We evaluate every dataset for fidelity, clinical plausibility, utility and privacy risk, and document the results. Your governance teams approve synthetic data based on evidence rather than assumptions about how safe or useful it is. Every report is shared with your teams.
Structured records, notes, messages, claims and device data for each synthetic patient tell the same story. Consistency across formats lets teams test complete workflows end to end, which fragmented synthetic datasets from separate tools simply cannot support. Workflows can be tested completely.
Synthetic data plugs into CI pipelines, test environments, demo systems and AI development workflows. Our PHI redaction services complement synthetic data where de-identified real data is still required for final validation. Fresh data is available whenever builds run, so testing never waits on data requests.
Synthetic datasets, generation pipelines, configurations and documentation belong to you. We hand everything over in documented form, so your teams can generate, extend and maintain synthetic data independently or continue with our support. No vendor lock-in applies to any component.
These are the questions engineering leaders, AI teams, product managers and privacy officers ask most often when they consider synthetic clinical data, whether they are removing PHI from test environments, speeding AI projects or enabling safe demonstrations. The answers are short on purpose. If your question depends on your data types, uses or privacy requirements, a short call with our team will give you a clearer answer. For related early-stage AI work, see our AI prototyping page before the call. Answers reflect our current practice, and our healthcare data quality services apply the same checks.
It is artificial healthcare data, such as patient records, notes, messages, claims and device readings, generated to look and behave like real clinical data without belonging to real people. It supports development, testing, demonstrations, training and AI prototyping with far lower privacy risk.
Synthetic data generated without real patient records generally does not contain PHI. Synthetic data derived from real records requires privacy assessment, because it may carry residual risk. We document generation methods and privacy evaluations so your compliance team can decide appropriately.
Synthetic data is excellent for prototyping, pipeline development and augmenting rare cases, but clinical AI should always be validated on real data before use. Most successful projects combine synthetic data for development with real data for final validation and monitoring.
Realism depends on the generation approach and quality checks. We evaluate statistical fidelity, clinical plausibility and utility for each intended use, so you know exactly where synthetic data matches reality and where limitations remain before relying on it. Reports make this clear.
At our $50 blended hourly rate, a defined synthetic dataset typically costs $4,000 to $15,000 and a reusable generation pipeline $15,000 to $50,000. Synthetic data derived from real records is scoped after a privacy assessment. Estimates list their assumptions clearly.
Yes. We generate notes that match each synthetic patient’s structured record, including realistic abbreviations and templates. Synthetic notes support NLP, RAG and documentation AI development without exposing real clinician documentation or the PHI it typically contains. Quality is reviewed by clinicians.
Share where your teams use real patient data today, which formats you need and what the data must support. In a 30-minute call we will identify where synthetic data can replace real PHI first and what it would take to generate it. Book a free consultation.
Your email address will not be published. Required fields are marked *
Our expert reaches out shortly after receiving your request and analyzing your requirements.
If needed, we sign an NDA to protect your privacy.
We request additional information to better understand and analyze your project.
We schedule a call to discuss your project, goals. and priorities, and provide preliminary feedback.
If you're satisfied, we finalize the agreement and start your project.